Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13738580 | 0.77 | PDE10A (0.40) | ALDH1A1KDM4EACHELMNAPOLB | |
| SCHEMBL16695052 | 0.71 | MEN1 (0.45) | ALDH1A1KDM4EACHEPOLBGAA | |
| SCHEMBL17436168 | 0.64 | HDAC6 (0.43) | ALDH1A1KDM4EGAAHPGDTDP1 | |
| SCHEMBL11195639 | 0.64 | TAAR1 (0.50) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL2437697 | 0.64 | HTR6 (0.43) | ADCY10ALDH1A1KDM4ELMNAPOLB | |
| SCHEMBL7584372 | 0.63 | ALDH1A1 (0.58) | ADCY10ALDH1A1LMNAPOLBGAA | |
| SCHEMBL3301625 | 0.62 | TAAR1 (0.59) | ALDH1A1KDM4ELMNA | |
| SCHEMBL27616376 | 0.61 | HTT (0.54) | LMNAGAAMAPTTDP1MEN1 | |
| SCHEMBL5412740 | 0.61 | MEN1 (0.39) | ADCY10ALDH1A1HPGDMAPTTDP1 | |
| SCHEMBL3802061 | 0.61 | TDP1 (0.38) | ADCY10ALDH1A1KDM4EHPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751106-B1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER IP GMBH (DE) | 2017-10-18 | — | — | EP | disclosed |
| EP-2822951-B1 | SUBSTITUTED AZABICYCLES AND USE THEREOF | BAYER IP GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-2822951-B1 | SUBSTITUTED AZABICYCLES AND USE THEREOF | BAYER IP GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-9498480-B2 | Substituted azabicycles and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| US-9498480-B2 | Substituted azabicycles and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| US-9498480-B2 | Substituted azabicycles and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| EP-2705037-B1 | SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIDAZINES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2705037-B1 | SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIDAZINES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-06-22 | — | — | EP | disclosed |
| US-9150580-B2 | Substituted imidazopyridines and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-9150580-B2 | Substituted imidazopyridines and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-20140171434-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIDAZINES AND THE USE THEREOF | BAYER PHARMA AKTIENGESSELLSCHAFT (DE) | 2014-06-19 | — | — | US | disclosed |
| US-20140113900-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| US-20140113900-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| US-20140113900-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| EP-2705038-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND THE USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-2705037-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIDAZINES AND THE USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-03-12 | — | — | EP | disclosed |
| WO-2013131923-A1 | SUBSTITUTED AZABICYCLES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-12 | — | — | WO | disclosed |
| WO-2013030288-A1 | SUBSTITUTED ANNELLATED PYRIMIDINE AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012152630-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012152629-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIDAZINES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171434-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND IMIDAZOPYRIDAZINES AND THE USE THEREOF | TPMT, PPIP5K2, DPP4 | ADCY10 4862/4885ALDH1A1 686/4885KDM4E 3827/4885 |
| US-20140113900-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND THE USE THEREOF | TPMT, TNNI3, PPIP5K2 | ADCY10 4845/4885ALDH1A1 818/4885KDM4E 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.